Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | Industry Therapeutic Update from Biohaven Pharmaceuticals: The Nurtec ODT: The First and Only Medication for the Acute and Preventive Treatment of Migraine

Monday 04/04/22
07:00 PM - 10:00 PM PDT Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
General Neurology
In this Industry Therapeutic Update, we will explore the data behind Nurtec® ODT (rimegepant), the only medication approved to both treat and prevent migraine attacks.
Nurtec® ODT is the only oral therapy that offers patients flexible control over their migraine with a single medication.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. 
 
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT Speaker Industry Therapeutic Update from Biohaven Pharmaceuticals: The Nurtec ODT: The First and Only Medication for the Acute and Preventive Treatment of Migraine
Faculty Disclosures
Eric J. Eross, DO No disclosure on file